Axial length, refraction, and retinal vascularization 1 year after ranibizumab or bevacizumab treatment for retinopathy of prematurity

Axial length, refraction, and retinal vascularization 1 year after ranibizumab or bevacizumab treatment for retinopathy of prematurity

Chun-Ju Lin,1,2 Yi-Yu Tsai1,2 1School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan; 2Department of Ophthalmology, China Medical University Hospital, China Medical University, Taichung, Taiwan Purpose: The purpose of this study was to report on the axial length, refrac...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Lin CJ, Tsai YY
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2016
Materias:
bevacizumab
ranibizumab
refraction
retinal vascularization
retinopathy of prematurity.
Ophthalmology
RE1-994
Acceso en línea:https://doaj.org/article/ce50a7fda98f4a9faa716882e547e831
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:ce50a7fda98f4a9faa716882e547e831
record_format dspace
spelling oai:doaj.org-article:ce50a7fda98f4a9faa716882e547e8312021-12-02T01:50:36ZAxial length, refraction, and retinal vascularization 1 year after ranibizumab or bevacizumab treatment for retinopathy of prematurity1177-5483https://doaj.org/article/ce50a7fda98f4a9faa716882e547e8312016-07-01T00:00:00Zhttps://www.dovepress.com/axial-length-refraction-and-retinal-vascularization-1-year-after-ranib-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Chun-Ju Lin,1,2 Yi-Yu Tsai1,2 1School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan; 2Department of Ophthalmology, China Medical University Hospital, China Medical University, Taichung, Taiwan Purpose: The purpose of this study was to report on the axial length, refraction, and retinal vascularization 1 year after ranibizumab or bevacizumab treatment for threshold retinopathy of prematurity.Methods: The authors conducted a comparative, consecutive, original study.Results: Twenty-five eyes of 13 patients with threshold retinopathy of prematurity received one intravitreal ranibizumab treatment, and 15 eyes of eight patients received one intravitreal bevacizumab treatment. In the ranibizumab group, the mean gestational age was 26.15±2.08 weeks, with a mean birth weight of 811.15±287.3 g. In the bevacizumab group, the mean gestational age was 26.50±2.14 weeks, with a mean birth weight of 938.38±200.4 g. The mean axial length was 20.34±0.97 mm and the mean spherical equivalent was 0.46±1.36 D in the ranibizumab group, with complete vascularization in 15 of 25 (60%) eyes. The mean axial length was 20.91±1.54 mm and the mean spherical equivalent was -0.60±3.86 D in the bevacizumab group, with complete vascularization in seven of 15 (46.7%) eyes.Conclusion: There were no significant differences in the axial length and refraction between children with threshold retinopathy of prematurity who received intravitreal bevacizumab compared to those who received ranibizumab after 1 year of follow-up. It appeared that the ranibizumab treatment could achieve more complete retinal vascularization than the bevacizumab treatment; however, there was no statistical significance and long-term follow-up is needed. Keywords: bevacizumab, ranibizumab, refraction, retinal vascularization, retinopathy of prematurity, axial lengthLin CJTsai YYDove Medical Pressarticlebevacizumabranibizumabrefractionretinal vascularizationretinopathy of prematurity.OphthalmologyRE1-994ENClinical Ophthalmology, Vol 2016, Iss Issue 1, Pp 1323-1327 (2016)
institution DOAJ
collection DOAJ
language EN
topic bevacizumab
ranibizumab
refraction
retinal vascularization
retinopathy of prematurity.
Ophthalmology
RE1-994
spellingShingle bevacizumab
ranibizumab
refraction
retinal vascularization
retinopathy of prematurity.
Ophthalmology
RE1-994
Lin CJ
Tsai YY
Axial length, refraction, and retinal vascularization 1 year after ranibizumab or bevacizumab treatment for retinopathy of prematurity
description Chun-Ju Lin,1,2 Yi-Yu Tsai1,2 1School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan; 2Department of Ophthalmology, China Medical University Hospital, China Medical University, Taichung, Taiwan Purpose: The purpose of this study was to report on the axial length, refraction, and retinal vascularization 1 year after ranibizumab or bevacizumab treatment for threshold retinopathy of prematurity.Methods: The authors conducted a comparative, consecutive, original study.Results: Twenty-five eyes of 13 patients with threshold retinopathy of prematurity received one intravitreal ranibizumab treatment, and 15 eyes of eight patients received one intravitreal bevacizumab treatment. In the ranibizumab group, the mean gestational age was 26.15±2.08 weeks, with a mean birth weight of 811.15±287.3 g. In the bevacizumab group, the mean gestational age was 26.50±2.14 weeks, with a mean birth weight of 938.38±200.4 g. The mean axial length was 20.34±0.97 mm and the mean spherical equivalent was 0.46±1.36 D in the ranibizumab group, with complete vascularization in 15 of 25 (60%) eyes. The mean axial length was 20.91±1.54 mm and the mean spherical equivalent was -0.60±3.86 D in the bevacizumab group, with complete vascularization in seven of 15 (46.7%) eyes.Conclusion: There were no significant differences in the axial length and refraction between children with threshold retinopathy of prematurity who received intravitreal bevacizumab compared to those who received ranibizumab after 1 year of follow-up. It appeared that the ranibizumab treatment could achieve more complete retinal vascularization than the bevacizumab treatment; however, there was no statistical significance and long-term follow-up is needed. Keywords: bevacizumab, ranibizumab, refraction, retinal vascularization, retinopathy of prematurity, axial length
format article
author Lin CJ
Tsai YY
author_facet Lin CJ
Tsai YY
author_sort Lin CJ
title Axial length, refraction, and retinal vascularization 1 year after ranibizumab or bevacizumab treatment for retinopathy of prematurity
title_short Axial length, refraction, and retinal vascularization 1 year after ranibizumab or bevacizumab treatment for retinopathy of prematurity
title_full Axial length, refraction, and retinal vascularization 1 year after ranibizumab or bevacizumab treatment for retinopathy of prematurity
title_fullStr Axial length, refraction, and retinal vascularization 1 year after ranibizumab or bevacizumab treatment for retinopathy of prematurity
title_full_unstemmed Axial length, refraction, and retinal vascularization 1 year after ranibizumab or bevacizumab treatment for retinopathy of prematurity
title_sort axial length, refraction, and retinal vascularization 1 year after ranibizumab or bevacizumab treatment for retinopathy of prematurity
publisher Dove Medical Press
publishDate 2016
url https://doaj.org/article/ce50a7fda98f4a9faa716882e547e831
work_keys_str_mv AT lincj axiallengthrefractionandretinalvascularization1yearafterranibizumaborbevacizumabtreatmentforretinopathyofprematurity
AT tsaiyy axiallengthrefractionandretinalvascularization1yearafterranibizumaborbevacizumabtreatmentforretinopathyofprematurity
_version_ 1718402866366906368

Ejemplares similares